AstraZeneca reports that its second-quarter results come in above expectations and that it keeps its full-year guidance unchanged. Business Line says core earnings for the three months ended June 30 rise 18% to $2.63 per share, while total revenue increases 5% to $15.38 billion at constant-currency rates. Investing.com similarly notes the company reiterates its annual guidance after exceeding Q2 profit expectations. Seeking Alpha’s reports characterize the beat in per-share terms, stating that AstraZeneca’s Q2 non-GAAP EPS exceeds expectations and that the company reconfirms its full-year outlook. Seeking Alpha also adds that the company raises its interim dividend alongside reaffirming guidance for 2026.
Across outlets, the common themes are that AstraZeneca delivers an earnings beat in the quarter, reports revenue growth on a constant-currency basis, and chooses to reconfirm rather than revise its annual financial expectations. The company also announces an increase to its interim dividend, which some coverage links to improved quarterly performance.
